Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid i biosynthesis

Nature Communications

Volumn 8, Issue , 2017, Pages

  Tran, Anh T ^a   Watson, Emma E ^a   Pujari, Venugopal ^b   Conroy, Trent ^a   Dowman, Luke J ^a   Giltrap, Andrew M ^a   Pang, Angel ^c   Wong, Weng Ruh ^d   Linington, Roger G ^d,e   Mahapatra, Sebabrata ^b   Saunders, Jessica ^f   Charman, Susan A ^f   West, Nicholas P ^g   Bugg, Timothy D H ^h   Tod, Julie ^h   Dowson, Christopher G ^h   Roper, David I ^h   Crick, Dean C ^b   Britton, Warwick J ^c   Payne, Richard J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Veterinary Dentistry and Oral Surgery   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SIMON FRASER UNIVERSITY   (Canada)

^f MONASH UNIVERSITY   (Australia)

^g UNIVERSITY OF QUEENSLAND   (Australia)

^h UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; DIHYDROSANSANMYCIN A; DIHYDROSANSANMYCIN B; DIHYDROSANSANMYCIN C; ISONIAZID; LIPID; NATURAL PRODUCTS AND THEIR SYNTHETIC DERIVATIVES; RIFAMPICIN; SANSANMYCIN A; SANSANMYCIN B; SANSANMYCIN C; SANSANMYCIN DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; BIOLOGICAL PRODUCT; LIPID I; MONOSACCHARIDE; OLIGOPEPTIDE; SANSANMYCIN; URIDINE;

ANTIMICROBIAL ACTIVITY; BACTERIUM; DISEASE INCIDENCE; DISEASE RESISTANCE; DISEASE SPREAD; DRUG; ENZYME; ENZYME ACTIVITY; ETIOLOGY; LIPID; MORBIDITY; MORTALITY; PEPTIDE; TUBERCULOSIS;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; LIPOGENESIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; BLOOD; CHEMISTRY; DRUG EFFECT; HUMAN; MOUSE;

CORYNEBACTERINEAE; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BIOLOGICAL PRODUCTS; HUMANS; MICE; MONOSACCHARIDES; MYCOBACTERIUM TUBERCULOSIS; OLIGOPEPTIDES; URIDINE;

EID: 85014452878     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14414     Document Type: Article

References (43)

1. World Health Organization. Global Tuberculosis Report 2015, (Geneva, Switzerland, 2015).
2. Zumla, A., Nahid, P. & Cole, S. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12, 388-404 (2013).
3. Gandhi, N. R. et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368, 1575-1580 (2006).
4. Chahine, E. B., Karaoui, L. R. & Mansour, H. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann. Pharmacother. 48, 107-115 (2014).
5. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70, 461-477 (2007).
6. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the last 25 years from 1991 to 2010. J. Nat. Prod. 75, 311-335 (2012).
7. Winn, M., Goss, R. J. M., Kimura, K. & Bugg, T. D. H. Antimicrobial nucleoside antibiotics targeting cell wall assembly: recent advances in structure-function studies and nucleoside biosynthesis. Nat. Prod. Rep. 27, 279-304 (2010).
8. Ichikawa, S., Yamaguchi, M. & Matsuda, A. Antibacterial nucleoside natural products inhibiting phospho-MurNAc-pentapeptide translocase; chemistry and structure-activity relationship. Curr. Med. Chem. 22, 3951-3979 (2015).
9. Isono, K. et al. Liposidomycins-novel nucleoside antibiotics which inhibit bacterial peptidoglycan synthesis. J. Antibiot. 38, 1617-1621 (1985).
10. Igarashi, M. et al. Caprazamycins, novel lipo-nucleoside antibiotics, from Streptomyces sp. J. Antibiot. 58, 327-337 (2005).
11. Yamaguchi, H. et al. Capuramycin, a new nucleoside antibiotic-taxonomy, fermentation, isolation and characterization. J. Antibiot. 39, 1047-1053 (1986).
12. Seto, H. et al. The structure of a new nucleoside antibiotic, capuramycin. Tetrahedron Lett. 29, 2343-2346 (1988).
13. McDonald, L. A. et al. Structures of the muraymycins, novel peptidoglycan biosynthesis inhibitors. J. Am. Chem. Soc. 124, 10260-10261 (2002).
14. Xie, Y., Chen, R., Si, S., Sun, C. & Xu, H. A new nucleosidyl-peptide antibiotic, sansanmycin. J. Antibiot. 60, 158-161 (2007).
15. Xie, Y., Xu, H., Si, S., Sun, C. & Chen, R. Sansanmycins B and C, new components of sansanmycins. J. Antibiot. 61, 237-240 (2008).
16. Xie, Y., Xu, H., Sun, C., Yu, Y. & Chen, R. Two novel nucleosidyl-peptide antibiotics: sansanmycin F and G produced by Streptomyces sp SS. J. Antibiot. 63, 143-146 (2010).
17. Li, Y.-B. et al. Synthesis and in vitro antitubercular evaluation of novel sansanmycin derivatives. Bioorg. Med. Chem. Lett. 21, 6804-6807 (2011).
18. Roy, A. D., Gruschow, S., Cairns, N. & Goss, R. J. Gene expression enabling synthetic diversification of natural products: chemogenetic generation of pacidamycin analogs. J. Am. Chem. Soc. 132, 12243-12245 (2010).
19. Rackham, E. J., Grüschow, S., Ragab, A. E., Dickens, S. & Goss, R. J. Pacidamycin biosynthesis: identification and heterologous expression of the first uridyl peptide antibiotic gene cluster. Chembiochem 11, 1700-1709 (2010).
20. Grüschow, S. et al. New pacidamycin antibiotics through precursor-directed biosynthesis. Chembiochem 10, 355-360 (2009).
21. Ragab, A. E., Grüschow, S., Rackham, E. J. & Goss, R. J. New pacidamycins biosynthetically: probing N-and C-terminal substrate specificity. Org. Biomol. Chem. 8, 3128-3129 (2010).
22. Ragab, A. E., Gruschow, S., Tromans, D. R. & Goss, R. J. Biogenesis of the unique 40, 50-dehydronucleoside of the uridyl peptide antibiotic pacidamycin. J. Am. Chem. Soc. 133, 15288-15291 (2011).
23. Boojamra, C. G. et al. Stereochemical elucidation and total synthesis of dihydropacidamycin D, a semisynthetic pacidamycin. J. Am. Chem. Soc. 123, 870-874 (2001).
24. Xie, Y. et al. NRPS substrate promiscuity leads to more potent antitubercular sansanmycin analogues. J. Nat. Prod. 77, 1744-1748 (2014).
25. Chung, B. C. et al. Structural insights into inhibition of lipid I production in bacterial cell wall synthesis. Nature 533, 557-560 (2016).
26. Spork, A. P. et al. Lead structures for new antibacterials: stereocontrolled synthesis of a bioactive muraymycin analogue. Chem. Eur. J. 20, 15292-15297 (2014).
27. Okamoto, K. et al. Total synthesis and biological evaluation of pacidamycin D and its 30-hydroxy analogue. J. Org. Chem. 77, 1367-1377 (2012).
28. Okamoto, K. et al. Synthesis of pacidamycin analogues via an Ugi-multicomponent reaction. Bioorg. Med. Chem. Lett. 22, 4810-4815 (2012).
29. Nakamura, H. et al. Total synthesis of (-)-caprazamycin A. Angew. Chem. Int. Ed. 54, 3136-3139 (2015).
30. Bozzoli, A., Kazmierski, W., Kennedy, G., Pasquarello, A. & Pecunioso, A. A solid-phase approach to analogues of the antibiotic mureidomycin. Bioorg. Med. Chem. Lett. 10, 2759-2763 (2000).
31. Ichikawa, S., Yamaguchi, M., Hsuan, L. S., Kato, Y. & Matsuda, A. Carbacaprazamycins: chemically stable analogues of the caprazamycin nucleoside antibiotics. ACS Infect. Dis. 1, 151-156 (2015).
32. Boojamra, C. G. et al. Synthetic dihydropacidamycin antibiotics: a modified spectrum of activity for the pacidamycin class. Bioorg. Med. Chem. Lett. 13, 3305-3309 (2003).
33. Howard, N. I. & Bugg, T. D. Synthesis and activity of 50-uridinyl dipeptide analogues mimicking the amino terminal peptide chain of nucleoside antibiotic mureidomycin A. Bioorg. Med. Chem. 11, 3083-3099 (2003).
34. Taneja, N. K. & Tyagi, J. S. Resazurin reduction assays for screening of antitubercular compounds against dormant and actively growing Mycobacterium tuberculosis, Mycobacterium bovis BCG and Mycobacterium smegmatis. J. Antimicrob. Chemother. 60, 288-293 (2007).
35. Wong, W. R., Oliver, A. G. & Linington, R. G. Development of antibiotic activity profile screening for the classification and discovery of natural product antibiotics. Chem. Biol. 19, 1483-1495 (2012).
36. Inukai, M., Isono, F. & Takatsuki, A. Selective inhibition of the bacterial translocase reaction in peptidoglycan synthesis by mureidomycins. Antimicrob. Agents Chemother. 37, 980-983 (1993).
37. Rodolis, M. T. et al. Mechanism of action of the uridyl peptide antibiotics: an unexpected link to a protein-protein interaction site in translocase MraY. Chem. Commun. 50, 13023-13025 (2014).
38. Siricilla, S., Mitachi, K., Skorupinska-Tudek, K., Swiezewska, E. & Kurosu, M. Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I. Anal. Biochem. 461, 36-45 (2014).
39. Siricilla, S., Mitachi, K., Wan, B., Franzblau, S. G. & Kurosu, M. Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitors. J. Antibiot. 68, 271-278 (2015).
40. Ishizaki, Y. et al. Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45. J. Biol. Chem. 288, 30309-30319 (2013).
41. Lloyd, A. J., Brandish, P. E., Gilbey, A. M. & Bugg, T. D. Phospho-N-acetylmuramyl-pentapeptide translocase from Escherichia coli: catalytic role of conserved aspartic acid residues. J. Bacteriol. 186, 1747-1757 (2004).
42. Mihalyi, A., Jamshidi, S., Slikas, J. & Bugg, T. D. Identification of novel inhibitors of phospho-MurNAc-pentapeptide translocase MraY from library screening: isoquinoline alkaloid michellamine B and xanthene dye phloxine B. Bioorg. Med. Chem. 22, 4566-4571 (2014).
43. Lloyd, A. J. et al. Characterization of tRNA-dependent peptide bond formation by MurM in the synthesis of Streptococcus pneumoniae peptidoglycan. J. Biol. Chem. 283, 6402-6417 (2008).